Search

Author/Creator Willenbacher, W.

3. NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY. (17th June 2021)

Authors:
Ansell, S. M.; Bröckelmann, P. J.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G. P.; Cohen, J. B.; De Boer, J. P.; Kuruvilla, J.; Savage, K. J.; Trneny, M.; Provencio, M.; Jaeger, U.; Willenbacher, W.; Swanink, R.; Sacchi, M.; Shipp, M. A.; Engert, A.; Armand, P.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2‐YEAR FOLLOW‐UP. (12th June 2019)

Authors:
Ansell, S.; Ramchandren, R.; Domingo‐Domènech, E.; Rueda, A.; Trněný, M.; Feldman, T.; Lee, H.; Provencio, M.; Sillaber, C.; Cohen, J.; Savage, K.; Willenbacher, W.; Sumbul, A.; Sacchi, M.; Armand, P.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
146
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL). (23rd June 2022)

Authors:
Ludwig, H.; Melchardt, T.; Sormann, S.; Zojer, N.; Andel, J.; Hartmann, B.; Tinchon, C.; Gunsilius, E.; Podar, K.; Egle, A.; Willenbacher, W.; Wöll, E.; Schreder, M.; Ruckser, R.; Bozic, B; Krauth, M.-T.; Petzer, A.; Schmitt, C; Machherndl-Spandl, S.; Agis, H.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
80
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL. (12th June 2019)

Authors:
Nowakowski, G.; Willenbacher, W.; Greil, R.; Larsen, T.S.; Patel, K.; Jäger, U.; Manges, R.F.; Trümper, L.; Haioun, C.; Everaus, H.; Kalakonda, N.; Knoble, J.; de Nully Brown, P.; Jørgensen, J.M.; Cunningham, D.; Domper Rubio, N.; Casadebaig, M.; Manzke, O.; Munoz, J.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
132
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗